<p>不列顛哥倫比亞省温哥華 --（Newsfile Corp. -2026 年 5 月 7 日）- Restart Life Sciences Corp.（CSE: HEAL）（FSE: HN30）（OTC Pink: NMLSF）（&#34;Restart Life&#34;或&#34;公司&#34;）很高興地宣佈 Lindsay Hamelin 被任命為公司獨立董事，立即生效。</p>
<p>Hamelin 女士擁有超過 20 年的資本市場和企業融資經驗，特別擅長企業結構、併購和公共公司環境中的融資策略。在她的職業生涯中，她支持並諮詢公共發行人處理複雜交易、資本籌集和旨在支持增長和提升股東價值的戰略企業發展計劃。</p>
<p>她的豐富經驗包括結構化和執行各種融資交易，包括股權發行和戰略資本計劃，以及在企業重組和併購活動方面提供諮詢。Hamelin 女士與管理團隊密切合作，使企業結構與長期戰略目標和資本市場執行保持一致。</p>
<p>&#34;我們非常高興歡迎 Lindsay 加入董事會，&#34;Restart Life 的首席執行官 Steve Loutskou 説。&#34;她在資本市場和併購方面的 20 年經驗為我們下一階段的戰略增長提供了所需的高層監督。隨着我們繼續評估戰略機會並在'更健康'的功能性食品和消費品市場中擴展，她的視角將極具價值。&#34;</p>
<p>Hamelin 女士的任命進一步加強了 Restart Life 的董事會，因為公司繼續推進其增長戰略，專注於嚴格的資本配置、企業發展以及在其品牌和知識產權組合中的擴展。</p>
<p>Restart Life Sciences 感謝其股東的持續支持，因為公司推進其使命並繼續執行其戰略。</p>
<p><strong>關於 Restart Life Sciences Corp.</strong></p>
<p>Restart Life Sciences Corp.是一家總部位於加拿大的生命科學公司，上市於 CSE。有關 Restart Life 的更多信息，請訪問公司網站 www.restartlife.co。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含構成&#34;前瞻性聲明&#34;的陳述。這些前瞻性聲明涉及已知和未知的風險、不確定性及其他因素，可能導致 Restart 的實際結果、表現或成就，或行業發展與預期結果、表現或成就存在重大差異。前瞻性聲明是指非歷史事實的陳述，通常但不總是通過&#34;預計&#34;、&#34;計劃&#34;、&#34;預期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;估計&#34;、&#34;項目&#34;、&#34;潛在&#34;及類似表達來識別，或事件或條件&#34;將&#34;、&#34;會&#34;、&#34;可能&#34;、&#34;能夠&#34;或&#34;應該&#34;發生。此信息和這些陳述在此稱為&#34;前瞻性聲明&#34;，並非歷史事實，均以本新聞稿日期為準，包括但不限於與收購的完成及相關先決條件的滿足或豁免及其時機、收購的預期利益、Restart 將 Holy Crap 的業務整合到其現有運營中的能力；垂直整合合作包裝設施的好處；預期的關閉日期，以及公司對 Holy Crap 的期望。</p>
<p>這些前瞻性聲明涉及眾多風險和不確定性，實際結果可能與任何前瞻性聲明中建議的結果存在重大差異。這些風險和不確定性包括但不限於：與收購相關的固有風險和不確定性、公司的財務狀況、預期收購的好處可能未能完全實現或實現所需時間比預期更長；市場波動；公司證券的金融市場狀況；以及一般商業、經濟、競爭、政治和社會不確定性。在本新聞稿中做出前瞻性聲明時，公司已應用若干重要假設，包括但不限於，滿足或豁免《最終協議》中所有關閉條件，Restart 將能夠成功將 Holy Crap 資產整合到其現有運營中；以及當前和未來的社會、經濟和政治條件。</p>
<p>儘管公司的管理層已嘗試識別可能導致實際結果與前瞻性聲明或前瞻性信息中包含的結果存在重大差異的重要因素，但可能還有其他因素導致結果未如預期、估計或意圖。不能保證這些聲明將被證明是準確的，因為實際結果和未來事件可能與這些聲明中表達或暗示的結果存在重大差異。因此，讀者不應對前瞻性聲明和前瞻性信息過度依賴。讀者被提醒，依賴這些信息可能不適合其他目的。公司不承擔更新任何前瞻性聲明、前瞻性信息或財務展望的責任，除非根據適用的證券法。鼓勵讀者查閲公司在某些加拿大省份向證券監管機構提交的持續披露文件，並可在 www.sedarplus.ca 獲取。</p>
<p>加拿大證券交易所及其市場監管機構（根據加拿大證券交易所政策定義的術語）對本公告的充分性或準確性不承擔責任。</p>
<p><strong>代表董事會</strong></p>
<p>Steve Loutskou</p>
<p>首席執行官，Restart Life Sciences Corp.</p>
<p>電話：+1 (778) 819-0244</p>
<p>電子郵件：hello@restartlife.co</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8801/296414_81085b4ad41f4a9e_logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8801/296414_81085b4ad41f4a9e_logo.jpg"/></p>
<p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/296414</p>
<p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296414/375?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296414/375"/></p>

RSLS

ATNF

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

<p>Restart Life Sciences Corp. 已任命 Lindsay Hamelin 為獨立董事，立即生效。她在資本市場和企業融資方面擁有超過 20 年的經驗，將為公司的戰略增長提供監督。首席執行官 Steve Loutskou 對她提升股東價值和支持公司在功能性食品和消費品市場擴展的能力表示信心。此次任命旨在加強董事會，因為 Restart Life 繼續其增長戰略和嚴格的資本配置</p>

<p>Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) (&#34;Restart Life&#34; or the &#34;Company&#34;) is pleased to announce the appointment of Lindsay Hamelin as an Independent Director of the Company, effective immediately.</p>
<div class="lb-trans"><p>不列顛哥倫比亞省温哥華 --（Newsfile Corp. -2026 年 5 月 7 日）- Restart Life Sciences Corp.（CSE: HEAL）（FSE: HN30）（OTC Pink: NMLSF）（&#34;Restart Life&#34;或&#34;公司&#34;）很高興地宣佈 Lindsay Hamelin 被任命為公司獨立董事，立即生效。</p>
</div><p>Ms. Hamelin brings over 20 years of capital markets and corporate finance experience, with a specific expertise in corporate structuring, mergers and acquisitions, and financing strategies within public company environments. Throughout her career, she has supported and advised public issuers on complex transactions, capital raises, and strategic corporate development initiatives designed to support growth and enhance shareholder value.</p>
<div class="lb-trans"><p>Hamelin 女士擁有超過 20 年的資本市場和企業融資經驗，特別擅長企業結構、併購和公共公司環境中的融資策略。在她的職業生涯中，她支持並諮詢公共發行人處理複雜交易、資本籌集和旨在支持增長和提升股東價值的戰略企業發展計劃。</p>
</div><p>Her extensive experience includes structuring and executing a wide range of financing transactions, including equity offerings and strategic capital initiatives, as well as advising on corporate reorganizations and M&amp;A activity. Ms. Hamelin has worked closely with management teams on aligning corporate structures with long-term strategic objectives and capital markets execution.</p>
<div class="lb-trans"><p>她的豐富經驗包括結構化和執行各種融資交易，包括股權發行和戰略資本計劃，以及在企業重組和併購活動方面提供諮詢。Hamelin 女士與管理團隊密切合作，使企業結構與長期戰略目標和資本市場執行保持一致。</p>
</div><p>&#34;We are very pleased to welcome Lindsay to the Board,&#34; said Steve Loutskou, CEO of Restart Life. &#34;Her 20-year track record in capital markets and M&amp;A provides us with the high-level oversight needed for our next phase of strategic growth. Her perspective will be highly valuable as we continue to evaluate strategic opportunities and execute on our expansion within the 'better-for-you' functional food and CPG markets.&#34;</p>
<div class="lb-trans"><p>&#34;我們非常高興歡迎 Lindsay 加入董事會，&#34;Restart Life 的首席執行官 Steve Loutskou 説。&#34;她在資本市場和併購方面的 20 年經驗為我們下一階段的戰略增長提供了所需的高層監督。隨着我們繼續評估戰略機會並在'更健康'的功能性食品和消費品市場中擴展，她的視角將極具價值。&#34;</p>
</div><p>Ms. Hamelin's appointment further strengthens Restart Life's Board as the Company continues to advance its growth strategy, with a focus on disciplined capital allocation, corporate development, and expansion within its portfolio of brands and intellectual property.</p>
<div class="lb-trans"><p>Hamelin 女士的任命進一步加強了 Restart Life 的董事會，因為公司繼續推進其增長戰略，專注於嚴格的資本配置、企業發展以及在其品牌和知識產權組合中的擴展。</p>
</div><p>Restart Life Sciences would like to thank its shareholders for their ongoing support as the Company advances its mission and continues to execute on its strategy.</p>
<div class="lb-trans"><p>Restart Life Sciences 感謝其股東的持續支持，因為公司推進其使命並繼續執行其戰略。</p>
</div><p><strong>About Restart Life Sciences Corp.</strong></p>
<div class="lb-trans"><p><strong>關於 Restart Life Sciences Corp.</strong></p>
</div><p>Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.</p>
<div class="lb-trans"><p>Restart Life Sciences Corp.是一家總部位於加拿大的生命科學公司，上市於 CSE。有關 Restart Life 的更多信息，請訪問公司網站 www.restartlife.co。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This news release contains statements that constitute &#34;forward-looking statements.&#34; Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words &#34;expects,&#34; &#34;plans,&#34; &#34;anticipates,&#34; &#34;believes,&#34; &#34;intends,&#34; &#34;estimates,&#34; &#34;projects,&#34; &#34;potential&#34; and similar expressions, or that events or conditions &#34;will,&#34; &#34;would,&#34; &#34;may,&#34; &#34;could&#34; or &#34;should&#34; occur. This information and these statements, referred to herein as &#34;forward-looking statements&#34;, are not historical facts, are made as of the date of this news release and include without limitation, statements relating to the closing of the Acquisition and the satisfaction or waiver of the related conditions precedent and the timing thereof, the perceived benefits of the Acquisition, the ability for Restart to integrate Holy Crap's business into its existing operations; the benefits of vertically integrating the co-packer facility; anticipated closing date, and the Company's expectations relating to Holy Crap.</p>
<div class="lb-trans"><p>本新聞稿包含構成&#34;前瞻性聲明&#34;的陳述。這些前瞻性聲明涉及已知和未知的風險、不確定性及其他因素，可能導致 Restart 的實際結果、表現或成就，或行業發展與預期結果、表現或成就存在重大差異。前瞻性聲明是指非歷史事實的陳述，通常但不總是通過&#34;預計&#34;、&#34;計劃&#34;、&#34;預期&#34;、&#34;相信&#34;、&#34;打算&#34;、&#34;估計&#34;、&#34;項目&#34;、&#34;潛在&#34;及類似表達來識別，或事件或條件&#34;將&#34;、&#34;會&#34;、&#34;可能&#34;、&#34;能夠&#34;或&#34;應該&#34;發生。此信息和這些陳述在此稱為&#34;前瞻性聲明&#34;，並非歷史事實，均以本新聞稿日期為準，包括但不限於與收購的完成及相關先決條件的滿足或豁免及其時機、收購的預期利益、Restart 將 Holy Crap 的業務整合到其現有運營中的能力；垂直整合合作包裝設施的好處；預期的關閉日期，以及公司對 Holy Crap 的期望。</p>
</div><p>These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the inherent risks and uncertainties associated with the Acquisition, the Company's financial condition, the risk that the anticipated benefits of the Acquisition may not be fully realized or take longer to realize than expected; market volatility; the state of the financial markets for the Company's securities; and general business, economic, competitive, political and social uncertainties;. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, the satisfaction or waiver of all closing conditions in the Definitive Agreement, that Restart will be able to successfully integrate the Holy Crap assets into its existing operations; and the current and future social, economic and political conditions.</p>
<div class="lb-trans"><p>這些前瞻性聲明涉及眾多風險和不確定性，實際結果可能與任何前瞻性聲明中建議的結果存在重大差異。這些風險和不確定性包括但不限於：與收購相關的固有風險和不確定性、公司的財務狀況、預期收購的好處可能未能完全實現或實現所需時間比預期更長；市場波動；公司證券的金融市場狀況；以及一般商業、經濟、競爭、政治和社會不確定性。在本新聞稿中做出前瞻性聲明時，公司已應用若干重要假設，包括但不限於，滿足或豁免《最終協議》中所有關閉條件，Restart 將能夠成功將 Holy Crap 資產整合到其現有運營中；以及當前和未來的社會、經濟和政治條件。</p>
</div><p>Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those expressed or implied in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. Readers are encouraged to read the Company's continuous disclosure documents filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca.</p>
<div class="lb-trans"><p>儘管公司的管理層已嘗試識別可能導致實際結果與前瞻性聲明或前瞻性信息中包含的結果存在重大差異的重要因素，但可能還有其他因素導致結果未如預期、估計或意圖。不能保證這些聲明將被證明是準確的，因為實際結果和未來事件可能與這些聲明中表達或暗示的結果存在重大差異。因此，讀者不應對前瞻性聲明和前瞻性信息過度依賴。讀者被提醒，依賴這些信息可能不適合其他目的。公司不承擔更新任何前瞻性聲明、前瞻性信息或財務展望的責任，除非根據適用的證券法。鼓勵讀者查閲公司在某些加拿大省份向證券監管機構提交的持續披露文件，並可在 www.sedarplus.ca 獲取。</p>
</div><p>Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.</p>
<div class="lb-trans"><p>加拿大證券交易所及其市場監管機構（根據加拿大證券交易所政策定義的術語）對本公告的充分性或準確性不承擔責任。</p>
</div><p><strong>On behalf of the Board of Directors</strong></p>
<div class="lb-trans"><p><strong>代表董事會</strong></p>
</div><p>Steve Loutskou</p>
<div class="lb-trans"><p>Steve Loutskou</p>
</div><p>Chief Executive Officer, Restart Life Sciences Corp.</p>
<div class="lb-trans"><p>首席執行官，Restart Life Sciences Corp.</p>
</div><p>Tel: +1 (778) 819-0244</p>
<div class="lb-trans"><p>電話：+1 (778) 819-0244</p>
</div><p>Email: hello@restartlife.co</p>
<div class="lb-trans"><p>電子郵件：hello@restartlife.co</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.newsfilecorp.com/files/8801/296414_81085b4ad41f4a9e_logo.jpg" alt="" original-src="https://images.newsfilecorp.com/files/8801/296414_81085b4ad41f4a9e_logo.jpg"/></p>
<p>To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296414</p>
<div class="lb-trans"><p>要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/296414</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://api.newsfilecorp.com/newsinfo/296414/375" alt="" original-src="https://api.newsfilecorp.com/newsinfo/296414/375"/></p>

Restart Life Sciences 任命資本市場資深人士 Lindsay Hamelin 加入董事會 | NMLSF 股票新聞